EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on Vaccination

Johanna Stoevesandt iD, Marc Schmalzing, Sophia Mohme, Matthias Goebeler iD

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025

DOI: 10.1111/ddg.15785 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Johanna Stoevesandt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: COVID-19, Dermatology, Practice Guidelines as Topic, Skin Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immunosuppressive and immunomodulatory treatment of dermatological patients necessitates the regular review and updating of standard vaccinations and vaccines indicated for specific conditions. The German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute regularly publishes evidence‐based vaccination recommendations, which are adapted to the current epidemiological situation and availability of vaccines. Since 2020, several changes have been made that are relevant for patients with dermato(onco)logical diseases: (1) COVID‐19 was defined as a new viral disease and several vaccines have been introduced; (2) in response to the global Mpox outbreak in 2022, a non‐replicating live vaccine based on the modified Ankara vaccinia virus, which was approved in 2013 for the prevention of smallpox, was given an indication extension; (3) a new inactivated high‐dose vaccine was approved for influenza vaccination of persons aged 60 years and older; (4) a new 20‐valent conjugate vaccine is available for pneumococcal vaccination; (5) two recombinant vaccines against the respiratory syncytial virus (RSV) were recently approved. This article discusses the correspondingly adapted STIKO recommendations for adults, with particular emphasis on their implementation in immunocompromised patients in dermatology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19DermatologyPractice Guidelines as TopicSkin DiseasesVaccinationAdultHumansCOVID-19 VaccinesGermanyImmunocompromised Host

Stichwörter der Autor:innen

COVID‐19Mpoxherpes zosterhigh‐dose vaccineimmunosuppressioninfluenzapneumococcirespiratory syncytial virus

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, University Hospital Würzburg, Würzburg, Germany.
  • Medizinische Klinik und Poliklinik II, Rheumatologie/Klinische Immunologie, University Hospital Würzburg, Würzburg, Germany.
  • Hautarztpraxis Dr. Mohme, Porta Westfalica, Germany.

ORCID-Profile: Johanna Stoevesandt, Matthias Goebeler

Zitieren

APA

Stoevesandt, J., Schmalzing, M., Mohme, S., & Goebeler, M. (2025). Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on Vaccination. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15785

Vancouver

Stoevesandt J, Schmalzing M, Mohme S, Goebeler M. Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on Vaccination. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15785

BibTeX
@article{Stoevesandt2025,
  author = {Stoevesandt, Johanna and Schmalzing, Marc and Mohme, Sophia and Goebeler, Matthias},
  title = {Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on Vaccination},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2025},
  doi = {10.1111/ddg.15785}
}
Kostenlos starten →